The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study

Authors: Fatih Kus MD, Deniz Can Guven PhD, Hasan Cagri Yildirim PhD, Baran Akagunduz PhD, Serdar Karakaya PhD, Osman Sutcuoglu PhD, Elvin Chalabiyev MD, Arif Akyildiz MD, Baris Koksal MD, Yigit Berk Sahin MD, Ece Karaca MD, Oguz Alp Kavruk MD, Nefise Tugce Zor MD, Firat Sirvan MD, Ozan Yazici PhD, Suayib Yalcin PhD

Source: Integrative Cancer Therapies, Vol 23 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1552-695X

Access URL: https://doaj.org/article/171b5c2135e74f2db40143086b69d588

Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

Authors: Hasan Cagri Yildirim, Fatih Kus, Deniz Can Guven, Ece Karaca, Yunus Kaygusuz, Omer Dizdar, Sercan Aksoy, Mustafa Erman, Suayib Yalcin, Saadettin Kilickap

Source: Journal of Immunotherapy and Precision Oncology, Vol 6, Iss 4, Pp 170-176 (2023)

Subject Terms: immunotherapy, nivolumab, biomarker, mean platelet volume to lymphocyte ratio, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://doaj.org/toc/2666-2345; https://doaj.org/toc/2590-017X

Access URL: https://doaj.org/article/67323cc7fe9e425d97196951b9a3b644

Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab

Authors: Hasan Cagri Yildirim, Hicran Anik, Deniz Ates Ozdemir, Rashad Ismayilov, Arif Akyildiz, Kerim Cayiroz, Fahri Ceyhan, Oguzalp Kavruk, Deniz Can Guven, Ozturk Ates, Alp Usubutun, Zafer Arik

Source: Biomolecules & Biomedicine (2024)

Subject Terms: Metastatic cervical cancer, squamous cell carcinoma (SCC), vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1 alpha (HIF-1 alpha), bevacizumab, Biology (General), QH301-705.5

File Description: electronic resource

Relation: https://www.bjbms.org/ojs/index.php/bjbms/article/view/10255; https://doaj.org/toc/2831-0896; https://doaj.org/toc/2831-090X

Access URL: https://doaj.org/article/0a6679b01dca4c8a82ddcef55b98579d

Knowledge and Protective Behaviors of Teachers on Skin Cancer: A Cross-Sectional Survey Study from Turkey

Authors: Celal Kus, Mine Mujde Kus, Hamit Sirri Keten, Huseyin Ucer, Numan Guvenc, Fatih Kus, Hasan Cagri Yildirim, Hatice Tuba Akbayram

Source: Children, Vol 10, Iss 2, p 291 (2023)

Subject Terms: skin cancer, primary prevention, sun safety, teacher, education, Pediatrics, RJ1-570

File Description: electronic resource

Relation: https://www.mdpi.com/2227-9067/10/2/291; https://doaj.org/toc/2227-9067

Access URL: https://doaj.org/article/d59a9d4299bb423eb2f1c8f9058f40df

Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19

Authors: Deniz Can Guven, Taha Koray Sahin, Oktay Halit Aktepe, Hasan Cagri Yildirim, Sercan Aksoy, Saadettin Kilickap

Source: Frontiers in Oncology, Vol 10 (2020)

Subject Terms: coronavirus disease 2019 (COVID-19), pandemic, oncologic care, patient education, questionnaire, coronavirus disease 2019 (COVID-19) fear, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/article/10.3389/fonc.2020.01553/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/dfaf098dbae44ddda50820ee4e73e894

Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

Authors: Feride Yılmaz, Serkan Yaşar, Ömer Denizhan Tatar, Hasan Çağrı Yıldırım, Deniz Can Güven, Arif Akyıldız, Elvin Chalabiyev, Burak Yasin Aktaş, Zafer Arık, Mustafa Erman

Source: BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)

Subject Terms: Irinotecan, Small cell lung cancer, Tolerability, Bi-weekly administration, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/d05ee6cbcd604c23bdd7f7e674ff535f

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

Authors: Hasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabiyev, Miraç Özen, Merve Keskinkılıç, Sercan Ön, Abdussamet Çelebi, Bengü Dursun, Ömer Acar, Seda Kahraman, Musa Barış Aykan, Ömür Kaman, Akif Doğan, Atike Pınar Erdoğan, Özde Melisa Celayir, Damla Günenç, Deniz Can Güven, İbrahim Vedat Bayoğlu, Tuğba Yavuzşen, İlhan Hacıbekiroğlu, Mevlüde İnanç, Saadettin Kılıçkap, Şuayib Yalçın, Sercan Aksoy

Source: Breast, Vol 66, Iss , Pp 85-88 (2022)

Subject Terms: Male breast cancer, Cyclin-dependent kinase 4–6 inhibitors, Palbociclib, Ribociclib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0960977622001631; https://doaj.org/toc/1532-3080

Access URL: https://doaj.org/article/18da86563ce64050a659105850fa47be